Loading…
Design and Production of a Chimeric Enzyme with Efficient Antibacterial Properties on Staphylococcus aureus
Improper use of antibiotics has alarmingly led to the emergence of antibiotic resistance. Hence, this necessitated an urgent need to find a suitable alternative to traditional antibiotics. Endolysins are enzymes produced at the end of the phage replication cycle and destroy the peptidoglycan of the...
Saved in:
Published in: | International journal of peptide research and therapeutics 2024-01, Vol.30 (1), p.7, Article 7 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Improper use of antibiotics has alarmingly led to the emergence of antibiotic resistance. Hence, this necessitated an urgent need to find a suitable alternative to traditional antibiotics. Endolysins are enzymes produced at the end of the phage replication cycle and destroy the peptidoglycan of the bacterial cell wall leading to the lysis of the host bacterial cell. These enzymes are species-specific, exhibit high lytic activity, and it is almost impossible for bacteria to develop resistance against them. Lysozyme subfamily 2 (LYZ2) is a modular region of the gene
61
(gp61) of phage φMR11 with lytic activity against
S. aureus
. However, it does not possess a cell wall recognition domain, which is usually found in lysins acting against gram-positive bacteria. Therefore, in this study, we engineered the LYZ2 by fusing a
Staphylococcus aureus
cell wall-binding domain (CBD) to its C-terminus and cloned the chimeric protein (named chimeric
Staphylococcus aureus
–targeting enzybiotic (CST
Enz
)) into the pET28a vector, and expressed the enzyme in
E. coli
BL21 (DE3) cell. The engineered lysin displayed a rapid and specific lytic activity against susceptible and Methicillin-resistant
Staphylococcus aureus
and inhibited the growth of the bacteria at concentrations higher than 0.5 µg/ml. Besides, the Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) of CST
Enz
were both approximately 64 times lower than those of LYZ2, indicating the increased bacteriolytic activity of the engineered version of the enzyme. In conclusion, the chimeric enzybiotic can be used as a potential antibacterial agent to limit infections caused by methicillin-resistant
Staphylococcus aureus
(MRSA). |
---|---|
ISSN: | 1573-3904 1573-3149 1573-3904 |
DOI: | 10.1007/s10989-023-10584-5 |